Leukemia

Patients who are in a period of active observation should feel comfortable sharing anything that seems abnormal with their healthcare provider. Read More ›

A greater number of comorbidities alone may not be sufficient to predict patient survival; age and stage at diagnosis must be considered as well. Read More ›

The first phase 3 trial comparing these drugs shows that acalabrutinib has similar efficacy as ibrutinib with a lower risk of a worrisome side effect. Read More ›

Although the use of telemedicine has been increasing due to the COVID-19 pandemic, it has not completely replaced the need for in-person visits. Read More ›

A federal law protects consumers from receiving bills covering the balance of many out-of-network emergency medical services. Read More ›

Combined acalabrutinib, venetoclax, and obinutuzumab have shown favorable efficacy and tolerability in untreated patients in an ongoing phase 2 study. Read More ›

The need to protect patients and healthcare workers from contracting COVID-19 has resulted in many changes to how hospital care is delivered. Read More ›

Recent data suggest that patients with CLL who received treatment with a BTK inhibitor had a rate of developing a second cancer over twice as high as that expected in the general population. Read More ›

Two oral health experts offer a thorough exploration of bone marrow transplants and how they relate to the mouth, with many tips for maintaining proper oral care during and after a transplant. Read More ›

The Food and Drug Administration (FDA) has expanded the use of the anticancer drug Imbruvica (ibrutinib) to be used in combination with rituximab for the treatment of the most common type of leukemia in adults, chronic lymphocytic leukemia (CLL), or its variant called small lymphocytic lymphoma (SLL). Read More ›